© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
April 05, 2021
The overuse of antibiotics in hospitals can lead to the emergence of drug-resistant strains of bacteria or outbreaks of infections by bacteria, such as Clostridiodes difficile (C. difficile).
March 29, 2021
Through investigating a type of toxin released by the most dangerous strains of C. diff, researchers now have a map for developing drugs that can block the toxin and prevent the bacteria from entering human cells.
March 22, 2021
The findings reveal a unique mechanism for C.diff survival in the human gut and suggest novel strategies for weakening its defenses, according to the study authors.
March 16, 2021
Although clostridioides difficile is the leading cause of health care-associated infection in the United States, there are currently only 2 antibiotics available for its treatment: vancomycin and fidaxomicin.
March 15, 2021
Findings show that an inflamed environment allows clostridioides difficile to thrive in an environment that is inhospitable to competing bacteria.
March 12, 2021
Fecal microbiota transplants (FMT) are highly successful in treating patients with Clostridioides difficile (C diff) infections, according to a study by the University of Birmingham.
March 11, 2021
The change in guidelines address how to assess damage to the kidneys caused by fluid loss associated with severe C. diff infection.
March 10, 2021
A commonly used drug made from secondary bile acids can affect the life cycle of Clostridioides difficile.
January 27, 2020
Fidaxomicin is a macrolide antibacterial medicine indicated to be used to treat infections that are proven or strongly suspected to be caused by C. difficile.
The easiest way to avoid misdiagnosis, inappropriate treatment, and potential loss of reimbursement is to prevent unsuitable testing.